APH

ALDA Pharmaceuticals Corp. (TSX VENTURE: APH)(OTCQB: APCSF) (the "Company" or "ALDA") announces that Natural Product Number ("NPN") 80026033 has been issued for a 0.5% hydrocortisone (0.5% HC) ointment. The Company is authorized to sell this product in Canada for temporary relief of minor skin irritations, rashes, itching and redness due to eczema, insect bites, poison ivy and other irritating plants; contact dermatitis caused by soaps, detergents, cosmetics, jewellery and other materials that irritate the skin; seborrheic dermatitis and psoriasis.

Typically, skin conditions of these types (which affect over 75% of Canadian adults at one time or another) begin as an inflammatory condition, but are often worsened or prolonged by secondary infection with bacteria or fungi (such as the fungi that causes athlete's foot). The combination of an effective anti-microbial product (such as the T36® formulation) with an anti-inflammatory agent (such as 0.5% hydrocortisone) would address this common medical condition more effectively and make treatment recommendations more straightforward for the health care provider and much easier to carry out for the patient. This innovative combination of an anti-microbial and anti-inflammatory therapy (avoiding the need to apply separate products to treat a single condition) represents an important step forward in the non-prescription therapeutic market. It is also consistent with the current approach favoured by a number of health providers encouraging Canadians to take charge in a positive way of their own care. Obtaining registration of a hydrocortisone ointment is a first step for the Company in bringing this approach to market.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T36® technology. The Company trades on the TSX Venture Exchange under the symbol APH.

Terrance G. Owen, Ph.D., MBA, President & CEO

ALDA Pharmaceuticals Corp.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains"," "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", "future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts: ALDA Pharmaceuticals Corp. Scott Young Investor Relations 604-377-5781 or 604-521-8300 Ext. 203 604-521-8322 (FAX) scott_young@aldacorp.com www.aldacorp.com